Home About us Contact
|
Home About us Contact | ||
|
|
||
LC/MS/MS Method (lc/ms/m + method)
Selected AbstractsHuman exposure to heterocyclic amine food mutagens/carcinogens: Relevance to breast cancer ,ENVIRONMENTAL AND MOLECULAR MUTAGENESIS, Issue 2-3 2002James S. Felton Abstract Heterocyclic amines produced from overcooked foods are extremely mutagenic in numerous in vitro and in vivo test systems. One of these mutagens, 2-amino-1-methyl-6-phenylimidazo[4,5- b]pyridine (PhIP), induces breast tumors in rats and has been implicated in dietary epidemiology studies as raising the risk of breast cancer in humans. Efforts in our laboratory and others have centered on defining the exposure to PhIP and other dietary mutagens derived from cooked food. We accomplish this by analyzing the foods with a series of solid-phase extractions and HPLC. We have developed an LC/MS/MS method to analyze the four major human PhIP metabolites (sulfates and glucuronides) following a single meal containing 27 ,g of cooking-produced PhIP in 200 g of grilled meat. Although the intake of PhIP was similar for each of eight women, the total amount excreted in the urine and the metabolite profiles differed among the subjects. It appears that adsorption (digestion) from the meat matrix, other foods in the diet, and genetic differences in metabolism may contribute to the variation. The four major metabolites that can be routinely assayed in the urine are N2 -OH-PhIP- N2 -glucuronide, PhIP- N2 -glucuronide, 4,-PhIP-glucuronide, and N2 -OH-PhIP- N3-glucuronide. This work is suited to investigate individual exposure and risk, especially for breast cancer, from these potent dietary mutagens. Environ. Mol. Mutagen. 39:112,118, 2002. Published 2002 Wiley-Liss, Inc. [source] Use of liquid chromatography,tandem mass spectrometry for quantitative analysis of clopyralid in compost and forageGRASSLAND SCIENCE, Issue 3 2009Ryuichi Uegaki Abstract In this study, we first developed a technique to quantify clopyralid using liquid chromatography,tandem mass spectrometry (LC/MS/MS) and tested its performance for compost and corn plant samples. Then, we measured the uptake of clopyralid by forage corn grown on two types of soil mixed with clopyralid-contaminated compost, in order to investigate the potential of ingestion of compost clopyralid by animals through forage crops. Because of the high recovery ratios (80,82% for compost and 98% for corn), sufficient theoretical quantification limits (5.0 and 1.7 ,g kg,1 fresh matter, respectively) and close agreement with the bioassay method (73 ,g kg,1 for LC/MS/MS and 80 ,g kg,1 for bioassay), the LC/MS/MS method was considered to be of potential value for determining clopyralid in compost and plant materials. Corn plants took up clopyralid from soil (compost), with the amount and rate of uptake varying with soil types and application of activated carbon to soil. There is a need for quantifying clopyralid uptake by a range of forage crops under a range of cultivation conditions (e.g. climate, soil, management) to estimate clopyralid fluxes through the manure,forage,animal,manure pathway. [source] Synthesis of d3 -cerivastatin for use as internal standard in a LC/MS/MS method developed for quantitation of the drug in human serumJOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS, Issue 4 2006Bang-Chi Chen Abstract d3 -Cerivastatin was synthesized as an internal standard for use in a LC/MS/MS method developed for the simultaneous quantitative determination of the drug in human serum. d3 -Cerivastatin was efficiently prepared on large scale from d3 -iodomethane using improved procedures. Copyright © 2006 John Wiley & Sons, Ltd. [source] Combination of liquid chromatography/tandem mass spectrometry and gas chromatography/mass spectrometry for the detection of 21 anabolic steroid residues in bovine urineJOURNAL OF MASS SPECTROMETRY (INCORP BIOLOGICAL MASS SPECTROMETRY), Issue 6 2005Christof Van Poucke Abstract For the detection of anabolic steroid residues in bovine urine, a highly sensitive liquid chromatographic/electrospray ionization tandem mass spectrometric (LC/ESI-MS/MS) method was developed using both positive and negative ionization. For four compounds the ESI mode was not sensitive enough and gas chromatographic/mass spectrometric GC/MS detection was therefore still necessary as a complementary method. The sample clean-up consisted of solid-phase extraction (SPE) on a C18 column followed by enzymatic hydrolysis and a second solid-phase extraction on a combination of a C18 and a NH2 column. After this last SPE clean-up, the eluate was split into two equal aliquots. One aliquot was further purified and after derivatization used for GC/MS analysis. The other aliquot was analyzed with LC/MS/MS in both ESI+ and ESI, modes. The method was validated according to the European Commission Decision 2002/657/EC. Decision limits (CC,) were between 0.16 and 1 ng ml,1 for the compounds detected with the LC/MS/MS method. The developed method is used in routine analysis in our laboratory. Copyright © 2005 John Wiley & Sons, Ltd. [source] Characterization of tanshinones with quinone reductase induction activity from Radix Salvia miltiorrhiza by liquid chromatography/tandem mass spectrometryRAPID COMMUNICATIONS IN MASS SPECTROMETRY, Issue 18 2009Zhongjun Ma Quinone reductase (QR) induction is a reliable biomarker of phase II enzyme induction. In this study, glutathione (GSH) was employed and a liquid chromatography/tandem mass spectrometry (LC/MS/MS) method was introduced to reveal the chemical constituents with QR activity from the ethyl acetate extract of roots Salvia miltiorrhiza (,Danshen') and nine tanshinones (9, 13, 17-19, 21, 24,26), which could conjugate with GSH, were characterized by LC/MS/MS and considered to have QR activities. Then, thirteen tanshinones, including six compounds (17, 18, 21, 24,26) of the above nine tanshinones, were isolated to conduct QR induction evaluation, and it was found that miltirone and its derivatives (18, 20, 24, 26) exhibited significant activities. The GSH conjugate abilities of the isolated tanshinones were also examined; this showed that compounds 18, 20, 24 and 26 had good conjugating abilities with GSH. Compared with the in vitro bioactivity screening results, this proved that conjugate ability is related with QR activity, so an LC/MS/MS method can be applied to find more active compounds. Copyright © 2009 John Wiley & Sons, Ltd. [source] A simplified protein precipitation/mixed-mode cation-exchange solid-phase extraction, followed by high-speed liquid chromatography/mass spectrometry, for the determination of a basic drug in human plasmaRAPID COMMUNICATIONS IN MASS SPECTROMETRY, Issue 18 2006Y.-J. Xue A simplified protein precipitation/mixed-mode cation-exchange solid-phase extraction (PPT/SPE) procedure has been investigated. A mixture of acetonitrile and methanol along with formic acid was used to precipitate plasma proteins prior to selectively extracting the basic drug. After vortexing and centrifugation, the supernatants were directly loaded onto an unconditioned Oasis® MCX µElution 96-well extraction plate, where the protonated drug was retained on the negatively charged sorbent while interfering neutral lipids, steroids or other endogenous materials were washed away. Normal wash steps were deemed unnecessary and not used before sample elution. The sample extracts were analyzed under both conventional and high-speed liquid chromatography/tandem mass spectrometry (LC/MS/MS) conditions to examine the feasibility of the PPT/SPE procedure for human plasma sample clean-up. For the conventional LC/MS/MS method, chromatographic separation was achieved on a C18, 2.1,×,50,mm column with gradient elution (k,,=,5.5). The mobile phase contained 0.1% formic acid in water and 0.1% formic acid in acetonitrile. For the high-speed LC/MS/MS method, chromatographic separation was achieved on a C18, 2.1,×,10,mm guard column with gradient elution (k,,=,2.2, Rt,=,0.26,min). The mobile phase contained 0.1% formic acid in water and 0.001% trifluoroacetic acid in acetonitrile. Detection for both conventional and high-speed LC/MS/MS methods was by positive ion electrospray tandem mass spectrometry on a ThermoElectron Finnigan TSQ Quantum Ultra, where enhanced resolution (RP 2000; 0.2,amu) was used for high-speed LC/MS/MS. The standard curve, ranging from 0.5 to 100,ng/mL, was fitted to a 1/x weighted quadratic regression model. This combined PPT/SPE procedure effectively eliminated time-consuming sorbent conditioning and wash steps, which are essential for a conventional mixed-mode SPE procedure, but retained the advantages of both PPT (removal of plasma proteins) and mixed-mode SPE (analyte selectivity). The validation results demonstrated that this PPT/SPE procedure was well suited for both conventional and high-speed LC/MS/MS analyses. In comparison with a conventional mixed-mode SPE procedure, the simplified PPT/SPE process provided comparable sample extract purity. This simple sample clean-up procedure can be applied to other basic compounds with minor modifications of PPT solvents. Copyright © 2006 John Wiley & Sons, Ltd. [source] Direct determination of phosphorylated intracellular anabolites of stavudine (d4T) by liquid chromatography/tandem mass spectrometryRAPID COMMUNICATIONS IN MASS SPECTROMETRY, Issue 16 2001Alain Pruvost The objective was to develop and validate a routine assay for active intracellular anabolites of stavudine (d4T), a nucleoside reverse transcriptase inhibitor in human PBMC, applicable to pharmacokinetic studies and treatment monitoring. This was achieved using liquid chromatography coupled to tandem mass spectrometry (LC/MS/MS), which theoretically allies optimum sensitivity, specificity and high sample throughput. After cellular lysis in a Tris/methanol buffer, the extract spiked with 2[H8]-ATP (internal standard) is directly injected into the LC/MS/MS system. Phosphorylated metabolites of d4T as well as deoxythymidine-triphosphate, the competitor on the reverse transcriptase, are separated from d4T on a reverse-phase microbore column with ion pairing. The detection is performed in the multiple reaction monitoring (MRM) mode after drug ionisation in negative mode electrospray. The limit of quantitation for d4T-TP was 138 fmol per 7,mL blood (9.8 fmol per 106 cells) and CV% for repeatability and intermediate precision were lower than 15%. Stability of compounds was checked before and during the process of isolation of PBMC. Cellular samples from several d4T-treated patients were successfully analysed using this method and d4T-triphosphate and deoxythymidine triphosphate were recovered. In conclusion, we have developed and validated a routine LC/MS/MS method that allows the simultaneous determination of mono-, di- and triphosphorylated anabolites of d4T in PBMC as well as the natural corresponding triphosphate in one analysis. For the first time, the chain terminator ratio (d4T-TP/dT-TP) could be directly measured. This method can be used simply and routinely on more than 35 samples per day. Extension to other nucleoside analogues is under development. Copyright © 2001 John Wiley & Sons, Ltd. [source] Development and validation of an on-line two-dimensional reversed-phase liquid chromatography,tandem mass spectrometry method for the simultaneous determination of prostaglandins E2 and F2, and 13,14-dihydro-15-keto prostaglandin F2, levels in human plasmaBIOMEDICAL CHROMATOGRAPHY, Issue 3 2009Junji Komaba Abstract We developed and validated an on-line reverse-phase two-dimensional LC/MS/MS (2D-LC/MS/MS) system for simultaneous determination of the levels of prostaglandin (PG) E2 as well as PGF2, and its metabolite 13,14-dihydro-15-keto PGF2, (F2, -M) in human plasma. Analytes were extracted by a three-step solid-phase extraction. Samples were then analyzed by on-line 2D-LC/MS/MS with electrospray ionization in negative mode. The 2D-LC system is composed of two reverse-phase analytical columns with a trapping column linking the two analytical columns. While an acidic buffer was used for both separation dimensions, differing organic solvents were employed for each dimension: methanol for the first and acetonitrile for the second to increase resolving power. The 2D-LC/MS/MS method was highly selective and sensitive with a significantly lower limit of quantitation (0.5 pg/mL for PGE2 and 2.5 pg/mL for PGF2, and F2, -M, respectively). Linearity of the 2D-LC/MS/MS system was demonstrated for the calibration ranges of 0.5,50 pg/mL for PGE2 and 2.5,500 pg/mL for PGF2, and F2, -M, respectively. Acceptable precision and accuracy were obtained throughout the calibration curve ranges. This highly selective and sensitive method was successfully utilized to determine the endogenous levels of PGE2, PGF2,, and F2, -M in plasma samples from six (four male and two female) normal volunteers. The mean concentrations for each analyte were 0.755 pg/mL for PGE2, 5.70 pg/mL for PGF2, and 9.48 pg/mL for F2, -M. Copyright © 2008 John Wiley & Sons, Ltd. [source] Quantitative LC/MS/MS method and in vivo pharmacokinetic studies of vitexin rhamnoside, a bioactive constituent on cardiovascular system from hawthornBIOMEDICAL CHROMATOGRAPHY, Issue 4 2007Mingjin Liang Abstract A simple and accurate liquid chromatography coupled with tandem mass spectrometry method was developed for determination and in vivo pharmacokinetic studies of vitexin rhamnoside in rat plasma. After protein precipitation using methanol, the analytes were separated by a Luna C18 column with an isocratic elution and analyzed by mass spectrometry in multiple reaction monitoring mode using the respective negative ion at m/z 577.2,293.0 for vitexin rhamnoside and m/z 593.2,413.0 for internal standard (IS) vitexin glucoside. The method was validated systematically within the concentration range 5,5000 µg/L (R > 0.996) and the lower limit of quantitation was 5 µg/L. Acceptable precision and accuracy were acquired for concentrations over the standard curve range. It was further applied to assess pharmacokinetics and bioavailability of vitexin rhamnoside after intravenous and oral administration to rats. The oral bioavailability of vitexin rhamnoside was only 3.57%, which indicated that vitexin rhamnoside had poor absorption or underwent extensive first-pass metabolism. Practical utility of this new LC/MS/MS method was confirmed in pilot pharmacokinetic studies in rats following both intravenous and oral administration. Copyright © 2007 John Wiley & Sons, Ltd. [source] Pharmacokinetics of lovastatin extended-release dosage form (Lovastatin XL) in healthy volunteersBIOPHARMACEUTICS AND DRUG DISPOSITION, Issue 4 2002Michael Lamson Abstract The purpose of this study was to evaluate pharmacokinetics and dose proportionality of lovastatin extended-release dosage form (ER-lovastatin) in the dosage levels of 10, 20 and 40 mg in 9 healthy male subjects. Each subject was randomized to receive a single oral dose of ER-lovastatin either 10, 20 or 40 mg in a three-way crossover design with a washout period of 7 days between the treatments. Subjects were served dinner at approximately 5:30 PM followed by dosing at approximately 10:00 PM in each study period. Serial plasma samples were collected up to 48 h after dosing and assayed for lovastatin and its active metabolite lovastatin acid using an LC/MS/MS method. The plasma concentration,time profiles of lovastatin and its active metabolite lovastatin acid exhibited delayed- and extended-release characteristics at each dose. Mean (±) values for the Cmax of lovastatin were 1.04±0.43, 2.03±0.65 and 4.03±3.02 ng/ml for the 10, 20 and 40 mg dosage, respectively. The corresponding values for the AUC0,48 h of lovastatin were 14.6±7.8, 34.1 ±13.7, and 53.9±35.6 ng h/ml. The same tendency was also found for Cmax and AUC0,48 h values of lovastatin acid. Results from this study demonstrated as the dose of ER-lovastatin increased from 10 to 40 mg, the Cmax and AUC0,48 h values of lovastatin as well as lovastatin acid appeared to increase linearly. Copyright © 2002 John Wiley & Sons, Ltd. [source] Clinical pharmacokinetic studies with INN 00835 (Nemifitide), a novel pentapeptide antidepressantBIOPHARMACEUTICS AND DRUG DISPOSITION, Issue 1 2002John P. Feighner Abstract Nemifitide (4-fluoro-L-phenylalanyl-trans-4-hydroxy-L-prolyl-L-arginylglycyl-L-tryptophanamide ditrifluoroacetate) is a novel antidepressant, currently in phase 2/3 clinical trials. The purpose of our phase 1 clinical trials (conducted over a three year period) was to provide safety and pharmacokinetic data to support its clinical development as an antidepressant drug. Single and multiple doses ranging from 18 to 320 mg were administered subcutaneously to healthy volunteers in five phase 1 studies. Plasma concentrations of unchanged parent drug were determined by a validated LC/MS/MS method in blood samples collected at timepoints between 10 min and 72 h after dosing. Nemifitide was rapidly absorbed (Cmax at 10 min) and eliminated (t1/2 15,30 min) in most subjects. Regression and power model analyses were used to evaluate the data. The results indicate that pharmacokinetic parameters: AUC0,t, AUC 0,, and Cmax, were close to dose proportional in the dose range investigated. There was no evidence of systemic accumulation of drug following 5 daily doses. No serious adverse events or clinically significant systemic adverse events occurred at any of the doses investigated in the over 100 subjects dosed in these studies. Drug-related adverse events were limited to local and transient skin reactions (pain and/or erythema) at the injection site, especially at the high doses administered: 240 and 320 mg. Copyright © 2002 John Wiley & Sons, Ltd. [source] Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjectsBRITISH JOURNAL OF CLINICAL PHARMACOLOGY, Issue 1 2007Yifan Zhang What is already known about this subject ,,Gliclazide has been considered metabolized by CYP2C9. ,,Its modified release formulation, gliclazide MR, shows low pharmacokinetic variability in Whites but high variability in Chinese. What this study adds ,,The results of this study show that the pharmacokinetics of gliclazide MR are affected mainly by CYP2C19 genetic polymorphism instead of CYP2C9 genetic polymorphism. ,,CYP2C19 genetic polymorphism might be responsible for the high pharmacokinetic variability of gliclazide MR in Chinese. Aims To investigate the influence of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics of gliclazide modified release (MR) in healthy Chinese subjects. Methods In a single-dose pharmacokinetic study, 24 healthy male subjects with various CYP2C9 and CYP2C19 genotypes received an oral dose of 30 mg gliclazide MR and plasma was sampled for 72 h postdose. In a multiple-dose pharmacokinetic study, 17 other CYP2C9*1 homozygotes with various CYP2C19 genotypes received 30 mg gliclazide MR once daily for 6 days and plasma was sampled after the last dose. The plasma concentrations of gliclazide were measured using a validated LC/MS/MS method. CYP2C9 and CYP2C19 genotypes were determined by polymerase chain reaction-restriction fragment length polymorphism analysis. Results In the single-dose study, no significant difference in any pharmacokinetic parameters was found in CYP2C9*1/*1, *1/*3 and *1/*13 subjects. In contrast, the AUC0,, of gliclazide was significantly increased by 3.4-fold [95% confidence interval (CI) 2.5, 4.7; P < 0.01] in CYP2C19 poor metabolizer (PM) subjects compared with CYP2C19*1 homozygotes. The half-life (t1/2) was prolonged from 15.1 to 44.5 h (P < 0.01). Similar differences were found in the multiple-dose study. The parameters of gliclazide AUCss, AUC0,, and Cmax were 3.4-fold (95% CI 2.9, 4.0), 4.5-fold (95% CI 3.8, 5.4) and 2.9-fold (95% CI 2.4, 3.4) increased (P < 0.01) in CYP2C19 PM subjects, respectively, compared with CYP2C19*1 homozygotes, and t1/2 was increased from 13.5 to 24.6 h (P < 0.01). Conclusions The pharmacokinetics of gliclazide MR are affected mainly by CYP2C19 genetic polymorphism instead of CYP2C9 genetic polymorphism. [source] | |||||||||||||